Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib

Lung Cancer

Volumn 59, Issue 1, 2008, Pages 81-87

  Fujiwara, Yoshiro ^a   Kiura, Katsuyuki ^a   Toyooka, Shinichi ^a   Hotta, Katsuyuki ^a   Tabata, Masahiro ^a   Takigawa, Nagio ^a   Soh, Junichi ^a   Tanimoto, Yasushi ^a   Kanehiro, Arihiko ^a   Kato, Katsuya ^a   Date, Hiroshi ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

EGFR mutation; Gefitinib; KL 6; Non small cell lung cancer; Prognostic factor

Indexed keywords

GEFITINIB; PROTEIN KL 6; SIALOGLYCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; EGFR GENE; FEMALE; GENE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; TREATMENT OUTCOME; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CA-15-3 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 37549020289     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.07.018     Document Type: Article

References (28)

1. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21 (2003) 2237-2246
2. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
3. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
4. Lee D.H., Han J.Y., Yu S.Y., Kim H.Y., Nam B.H., Hong E.K., et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol 1 (2006) 965-971
5. Yang C., Yu C., Chen K., Lin Z., Kuo S., Hwang T., et al. A phase II study of gefitinib as first line treatment for good performance advanced or metastatic non-small cell lung cancer in East Asian patients. Proc Am Soc Clin Oncol 24 (2006) (Abstract 7167)
6. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 (2005) 2513-2520
7. Hotta K., Kiura K., Toyooka S., Takigawa N., Soh J., Fujiwara Y., et al. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2 (2007) 632-637
8. Tokumo M., Toyooka S., Kiura K., Shigematsu H., Tomii K., Aoe M., et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11 (2005) 1167-1173
9. Ichihara S., Toyooka S., Fujiwara Y., Hotta K., Shigematsu H., Tokumo M., et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 120 (2007) 1239-1247
10. Johnson B.E., and Janne P.A. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 65 (2005) 7525-7529
11. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
12. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 (2005) 6829-6837
13. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 (2005) e17
14. Giaccone G., Janmaat M., Ruiz M.G., Rodriguez J., LeChevalier T., Thatcher N., et al. EGFR mutations do not accurately predict response to erlotinib in first-line monotherapy treatment of advanced non-small-cell lung cancer. Lung Cancer 49 (2005) S244 (P-485)
15. Kohno N., Kyoizumi S., Awaya Y., Fukuhara H., Yamakido M., and Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 96 (1989) 68-73
16. Kohno N., Akiyama M., Kyoizumi S., Hakoda M., Kobuke K., and Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 18 (1988) 203-216
17. Hirasawa Y., Kohno N., Yokoyama A., Inoue Y., Abe M., and Hiwada K. KL-6 a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol 17 (1997) 501-507
18. Guddo F., Giatromanolaki A., Koukourakis M.I., Reina C., Vignola A.M., Chlouverakis G., et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 51 (1998) 667-671
19. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
20. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24 (2006) 3340-3346
21. Sutani A., Nagai Y., Udagawa K., Uchida Y., Koyama N., Murayama Y., et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95 (2006) 1483-1489
22. Okamoto I., Kashii T., Urata Y., Hirashima T., Kudoh S., Ichinose Y., et al. EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer (NSCLC) patients (pts): results of West Japan Thoracic Oncology Group trial (WJTOG0403). Proc Am Soc Clin Oncol 24 (2006) (Abstract 7073)
23. Sunaga N., Yanagitani N., Kaira K., Tomizawa Y., Iijima H., Otani Y., et al. Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations. Proc Am Soc Clin Oncol 24 (2006) (Abstract 7183)
24. Moriyama M., Matsumura H., Watanabe A., Nakamura H., Arakawa Y., Oshiro S., et al. Detection of serum and intrahepatic KL-6 in anti-HCV positive patients with hepatocellular carcinoma. Hepatol Res 30 (2004) 24-33
25. Hollingsworth M.A., and Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4 (2004) 45-60
26. Witta S.E., Gemmill R.M., Hirsch F.R., Coldren C.D., Hedman K., Ravdel L., et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66 (2006) 944-950
27. Inata J., Hattori N., Yokoyama A., Ohshimo S., Doi M., Ishikawa N., et al. Circulating KL-6/MUC1 mucin carrying sialyl Lewisa oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma. Int J Cancer 120 (2007) 2643-2649
28. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., Harita S., et al. Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Ann Oncol 16 (2005) 1817-1823